ZA200509851B - Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superinfections and fungal recurrences - Google Patents
Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superinfections and fungal recurrences Download PDFInfo
- Publication number
- ZA200509851B ZA200509851B ZA200509851A ZA200509851A ZA200509851B ZA 200509851 B ZA200509851 B ZA 200509851B ZA 200509851 A ZA200509851 A ZA 200509851A ZA 200509851 A ZA200509851 A ZA 200509851A ZA 200509851 B ZA200509851 B ZA 200509851B
- Authority
- ZA
- South Africa
- Prior art keywords
- use according
- formulation
- ascorbic acid
- fungal
- vaginal
- Prior art date
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims description 103
- 229960005070 ascorbic acid Drugs 0.000 title claims description 48
- 235000010323 ascorbic acid Nutrition 0.000 title claims description 45
- 239000011668 ascorbic acid Substances 0.000 title claims description 45
- 238000011282 treatment Methods 0.000 title claims description 21
- 230000002538 fungal effect Effects 0.000 title claims description 13
- 206010042566 Superinfection Diseases 0.000 title claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims description 28
- 238000009472 formulation Methods 0.000 claims description 19
- 241000222122 Candida albicans Species 0.000 claims description 14
- 206010017533 Fungal infection Diseases 0.000 claims description 11
- 208000031888 Mycoses Diseases 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 5
- 229960002509 miconazole Drugs 0.000 claims description 5
- 239000002324 mouth wash Substances 0.000 claims description 5
- 230000002035 prolonged effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 210000004761 scalp Anatomy 0.000 claims description 4
- 210000001215 vagina Anatomy 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 229960000282 metronidazole Drugs 0.000 claims description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 238000011272 standard treatment Methods 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 229940095731 candida albicans Drugs 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims 3
- 241001480043 Arthrodermataceae Species 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000003716 antitrichomonal agent Substances 0.000 claims 1
- 230000037304 dermatophytes Effects 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 description 11
- 201000003984 candidiasis Diseases 0.000 description 11
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 10
- 208000035415 Reinfection Diseases 0.000 description 9
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 9
- 230000000306 recurrent effect Effects 0.000 description 9
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010046914 Vaginal infection Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 210000005000 reproductive tract Anatomy 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000001857 anti-mycotic effect Effects 0.000 description 3
- 239000002543 antimycotic Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010047623 Vitamin C deficiency Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 208000010233 scurvy Diseases 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000003 vaginal tablet Substances 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 206010002064 Anaemia macrocytic Diseases 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029783 Normochromic normocytic anaemia Diseases 0.000 description 1
- 206010030154 Oesophageal candidiasis Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000005655 esophageal candidiasis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000006437 macrocytic anemia Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000005001 male reproductive tract Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- -1 pessaries Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000005582 sexual transmission Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 244000000072 vaginal pathogen Species 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 229940044977 vaginal tablet Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03077314A EP1500394A1 (en) | 2003-07-22 | 2003-07-22 | Pharmaceutical compositions comprising ascorbic acid or the treatment of fungal superinfections and fungal recurrences |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200509851B true ZA200509851B (en) | 2007-03-28 |
Family
ID=33483977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200509851A ZA200509851B (en) | 2003-07-22 | 2004-05-21 | Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superinfections and fungal recurrences |
Country Status (23)
Country | Link |
---|---|
US (1) | US7863326B2 (el) |
EP (2) | EP1500394A1 (el) |
JP (1) | JP4791358B2 (el) |
KR (1) | KR101100713B1 (el) |
CN (1) | CN100540000C (el) |
AR (1) | AR045070A1 (el) |
AT (1) | ATE413171T1 (el) |
BR (1) | BRPI0412453A (el) |
CA (1) | CA2528879A1 (el) |
CY (1) | CY1108684T1 (el) |
DE (1) | DE602004017613D1 (el) |
DK (1) | DK1646378T3 (el) |
EA (1) | EA010241B1 (el) |
ES (1) | ES2314406T3 (el) |
HK (1) | HK1092693A1 (el) |
HR (1) | HRP20090022T3 (el) |
MX (1) | MXPA05013798A (el) |
PL (1) | PL1646378T3 (el) |
PT (1) | PT1646378E (el) |
SI (1) | SI1646378T1 (el) |
UA (1) | UA88446C2 (el) |
WO (1) | WO2005013971A1 (el) |
ZA (1) | ZA200509851B (el) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1850829A4 (en) * | 2005-02-03 | 2012-12-26 | Taro Pharmaceuticals Usa Inc | NEW PROPOLFOL COMPOSITION WITH ASCORBIC ACID OR PHARMACEUTICALLY USEFUL SALTS |
US20090197946A1 (en) * | 2008-01-31 | 2009-08-06 | Joseph Di Bartolomeo | Composition and method for treatment of inflamation and infections of the genitalia, contraceptive and the prophylaxis of sexually transmitted diseases |
FI20095550A0 (fi) * | 2009-05-19 | 2009-05-19 | Bayer Schering Pharma Oy | Vaginaalinen antojärjestelmä |
BRPI1101853A2 (pt) * | 2010-04-08 | 2015-08-11 | Univ Florida | Sistema de vetor de expressão transitória com base viral que permite múltiplas aplicações |
DE102012009057A1 (de) | 2012-05-09 | 2013-11-14 | Dr. Arabin GmbH & Co. KG | Rotationspessar mit zusätzlicher Wirkstoffkomponente |
FR3018193B1 (fr) * | 2014-03-10 | 2017-09-08 | Probionov | Comprime vaginal muco-adhesif a liberation prolongee |
US11865139B2 (en) * | 2020-11-12 | 2024-01-09 | Thermolife International, Llc | Method of treating migraines and headaches |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4229430A (en) * | 1978-08-21 | 1980-10-21 | Fahim Mostafa S | Oral composition for improving oral health |
JPH01125306A (ja) * | 1987-11-09 | 1989-05-17 | Daiichi Seimo Kk | 赤腐れ菌の防除剤 |
DE59101214D1 (de) * | 1991-07-15 | 1994-04-21 | Artesan Pharma Gmbh | Verwendung der Ascorbinsäure zur Zubereitung von Arzneimitteln zur Anwendung im Genitalbereich. |
US5425944A (en) * | 1992-10-27 | 1995-06-20 | Harich; Jakob | Antimicrobial grapefruit extract |
US6416779B1 (en) * | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
CN1245074A (zh) * | 1998-04-26 | 2000-02-23 | 曾忠铭 | 减弱阴道酸度的药剂和用途 |
US6153635A (en) * | 1998-11-20 | 2000-11-28 | Upmalis; David H. | Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate |
JP2000169370A (ja) * | 1998-12-09 | 2000-06-20 | Frontier:Kk | 肉食動物用皮膚疾患治療薬及び健康食品 |
DE29900513U1 (de) * | 1999-01-14 | 2000-08-10 | Rst Icking Gmbh | Schuh- bzw. Fuß-Hygienemittel |
RU2150935C1 (ru) * | 1999-06-22 | 2000-06-20 | Московский государственный медико-стоматологический университет | Защитно-профилактический крем |
US6391330B1 (en) * | 2000-05-11 | 2002-05-21 | Michael A. Ross | Proanthocyanidins and ascorbic acid composition for topical application to human respiratory and oral mucosa |
US20030130225A1 (en) * | 2001-10-16 | 2003-07-10 | Nawaz Ahmad | Novel methods of treating local fungal and bacterial infections |
-
2003
- 2003-07-22 EP EP03077314A patent/EP1500394A1/en not_active Withdrawn
-
2004
- 2004-05-21 CA CA002528879A patent/CA2528879A1/en not_active Withdrawn
- 2004-05-21 CN CNB2004800183098A patent/CN100540000C/zh not_active Expired - Fee Related
- 2004-05-21 AT AT04739316T patent/ATE413171T1/de active
- 2004-05-21 EP EP04739316A patent/EP1646378B1/en active Active
- 2004-05-21 US US10/563,912 patent/US7863326B2/en active Active
- 2004-05-21 SI SI200430949T patent/SI1646378T1/sl unknown
- 2004-05-21 PT PT04739316T patent/PT1646378E/pt unknown
- 2004-05-21 MX MXPA05013798A patent/MXPA05013798A/es active IP Right Grant
- 2004-05-21 DE DE602004017613T patent/DE602004017613D1/de active Active
- 2004-05-21 UA UAA200600565A patent/UA88446C2/uk unknown
- 2004-05-21 JP JP2006520679A patent/JP4791358B2/ja not_active Expired - Fee Related
- 2004-05-21 ES ES04739316T patent/ES2314406T3/es active Active
- 2004-05-21 PL PL04739316T patent/PL1646378T3/pl unknown
- 2004-05-21 DK DK04739316T patent/DK1646378T3/da active
- 2004-05-21 KR KR1020057024553A patent/KR101100713B1/ko not_active IP Right Cessation
- 2004-05-21 BR BRPI0412453-7A patent/BRPI0412453A/pt not_active Application Discontinuation
- 2004-05-21 EA EA200600176A patent/EA010241B1/ru not_active IP Right Cessation
- 2004-05-21 ZA ZA200509851A patent/ZA200509851B/en unknown
- 2004-05-21 WO PCT/EP2004/005559 patent/WO2005013971A1/en active Application Filing
- 2004-07-21 AR ARP040102588A patent/AR045070A1/es unknown
-
2006
- 2006-09-22 HK HK06110599.8A patent/HK1092693A1/xx not_active IP Right Cessation
-
2008
- 2008-12-31 CY CY20081101515T patent/CY1108684T1/el unknown
-
2009
- 2009-01-16 HR HR20090022T patent/HRP20090022T3/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN100540000C (zh) | 2009-09-16 |
EP1500394A1 (en) | 2005-01-26 |
JP4791358B2 (ja) | 2011-10-12 |
CA2528879A1 (en) | 2005-02-17 |
EP1646378B1 (en) | 2008-11-05 |
BRPI0412453A (pt) | 2006-10-17 |
HK1092693A1 (en) | 2007-02-16 |
PT1646378E (pt) | 2008-12-17 |
SI1646378T1 (sl) | 2009-02-28 |
DE602004017613D1 (de) | 2008-12-18 |
US7863326B2 (en) | 2011-01-04 |
EA010241B1 (ru) | 2008-06-30 |
WO2005013971A1 (en) | 2005-02-17 |
PL1646378T3 (pl) | 2009-04-30 |
CY1108684T1 (el) | 2014-04-09 |
MXPA05013798A (es) | 2006-06-27 |
JP2006528138A (ja) | 2006-12-14 |
EP1646378A1 (en) | 2006-04-19 |
EA200600176A1 (ru) | 2006-06-30 |
KR20060040603A (ko) | 2006-05-10 |
CN1812781A (zh) | 2006-08-02 |
AR045070A1 (es) | 2005-10-12 |
ES2314406T3 (es) | 2009-03-16 |
US20070037880A1 (en) | 2007-02-15 |
ATE413171T1 (de) | 2008-11-15 |
KR101100713B1 (ko) | 2011-12-30 |
UA88446C2 (uk) | 2009-10-26 |
HRP20090022T3 (en) | 2009-02-28 |
DK1646378T3 (da) | 2009-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5741525A (en) | Vaginal pharmaceutical hydrogen peroxide composition | |
US8765819B2 (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof | |
WO2006114061A1 (fr) | Composition et procédé de régulation et de maintien de la flore bactérienne vaginale et de l'acidité normale dans le vagin | |
JP2004529935A (ja) | 外陰部膣炎と膣症とを治療するための抗真菌剤を含む組成物 | |
AU2002312416A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
EP0746313B1 (en) | Use of a composition comprising alpha hydroxy organic acid for the manufacture of a medicament for the treatment of small mouth ulcers | |
US7863326B2 (en) | Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superinfections and fungal recurrences | |
HU228669B1 (en) | Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome | |
WO2020025657A1 (en) | Composition for use in the prevention and/or treatment of the genitourinary mucosa | |
US20060264857A1 (en) | Absorbent articles with buffer | |
CN110787078A (zh) | 一种含有甘草黄酮的牙膏及其制备方法和应用 | |
US7687078B1 (en) | Method of treatment | |
EP3817738A1 (en) | Compositions and methods for treatment of oral ulceration and oral mucositis | |
CN111632073A (zh) | 一种抗菌消炎的女性私密益生菌组合物及其制备 | |
AU2006234397B2 (en) | Novel use of zinc gluconate for treating hydradenitis suppurativa | |
KR100797557B1 (ko) | 생식기 염증 예방 또는 치료용 약제학적 조성물 | |
RU2262948C1 (ru) | Способ лечения кандидозного вульвовагинита у беременных | |
KR20210133495A (ko) | 옥수수불검화 정량 추출물 및 후박 추출물을 유효성분으로 포함하며 iLet(innovative Low excipient tablet) 기술을 이용한 정제사이즈 축소를 통해 복용 편의성이 향상된 치주질환 예방 또는 치료용 약학적 조성물 | |
Johnston | Over-the-counter vaginal preparations | |
Kirichenko | The course of treatment with Miramistin. How to do douching with Miramistin | |
MXPA06008279A (en) | Fluconazole-tinidazole combination for the treatment of vaginal infections, composition thereof and preparation and use of same |